Related Experiment Video
Updated: Jul 11, 2026
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
Identification of genes associated with tumorigenesis of meibomian cell carcinoma by microarray analysis
Arun Kumar1, Syril Kumar Dorairaj, Venkatesh C Prabhakaran
1Department of Molecular Reproduction, Development, and Genetics, Indian Institute of Science, Bangalore 560012, India. karun@mrdg.iisc.ernet.in
Abstract:
Meibomian cell carcinoma (MCC) is a malignant tumor of the meibomian glands located in the eyelids. No information exists on the cytogenetic and genetic aspects of MCC. There is no report on the gene expression profile of MCC. Thus there is a need, for both scientific and clinical reasons, to identify genes and pathways that are involved in the development and progression of MCC. We analyzed the gene expression profile of MCC by the microarray technique. Forty-four genes were upregulated and 149 genes were downregulated in MCC. Differential expression data were confirmed for 5 genes by semiquantitative RT-PCR in MCC tumors: GTF2H4, RBM12, UBE2D3, DDX17, and LZTS1. We found dysregulation of two major pathways in MCC: MAPK and JAK/STAT. Clusters of genes on chromosomes 1, 12, and 19 were dysregulated in MCC. The data presented here will facilitate the identification of specific markers and therapeutic targets for the treatment of MCC patients.
Insights
This study reveals key gene expression changes in Meibomian cell carcinoma (MCC), identifying upregulated and downregulated genes and pathways. These findings offer potential new markers and therapeutic targets for this eyelid cancer.
Area of Science:
- Ophthalmology
- Oncology
- Molecular Biology
Background:
- Meibomian cell carcinoma (MCC) is an eyelid malignancy with unknown cytogenetic and genetic profiles.
- Gene expression data for MCC is currently unavailable, hindering the understanding of its development and progression.
Purpose of the Study:
- To investigate the gene expression profile of Meibomian cell carcinoma (MCC).
- To identify specific genes, pathways, and chromosomal regions involved in MCC development and progression.
- To lay the groundwork for identifying novel diagnostic markers and therapeutic targets for MCC.
Main Methods:
- Gene expression profiling was performed using microarray technology on MCC tumors.
- Differential gene expression was validated for five specific genes (GTF2H4, RBM12, UBE2D3, DDX17, LZTS1) using semiquantitative RT-PCR.
- Analysis included identifying dysregulated pathways and chromosomal gene clusters.
Main Results:
- Microarray analysis identified 44 upregulated and 149 downregulated genes in MCC.
- Semiquantitative RT-PCR confirmed differential expression of GTF2H4, RBM12, UBE2D3, DDX17, and LZTS1.
- The MAPK and JAK/STAT signaling pathways were found to be dysregulated in MCC.
- Gene clusters on chromosomes 1, 12, and 19 showed dysregulation.
Conclusions:
- This study provides the first comprehensive gene expression profile of Meibomian cell carcinoma (MCC).
- The identified dysregulated genes and pathways (MAPK, JAK/STAT) are critical for understanding MCC pathogenesis.
- The findings pave the way for developing targeted therapies and diagnostic markers for MCC patients.
